Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue

Trial Profile

Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 May 2018

At a glance

  • Drugs Brimonidine/brinzolamide (Primary) ; Bimatoprost; Latanoprost; Travoprost
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 28 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 03 Jan 2018 Planned End Date changed from 22 Feb 2018 to 1 Feb 2018.
    • 03 Jan 2018 Planned primary completion date changed from 22 Feb 2018 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top